Kyoichi Kaira

List of Publications by Year
in descending order

260	6,084	87843 38	123376 61
papers	citations	h-index	g-index

266	266	266	6773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1242-1246.	0.5	177
2	Metabolic activity by 18Fâ€“FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 56-66.	3.3	166
3	CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research, 2020, 8, 334-344.	1.6	155
4	Biologic Correlation of 2-[¹⁸F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors. Journal of Clinical Oncology, 2010, 28, 3746-3753.	0.8	143
5	Efficacy of gefitinib for nonâ€adenocarcinoma nonâ€smallâ€cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Science, 2011, 102, 1032-1037.	1.7	128
6	<scp>l</scp>â€type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Science, 2008, 99, 2380-2386.	1.7	126
7	Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer, 2008, 59, 203-210.	0.9	125
8	Transport of 3-Fluoro-l-Î±-Methyl-Tyrosine by Tumor-Upregulated L-Type Amino Acid Transporter 1: A Cause of the Tumor Uptake in PET. Journal of Nuclear Medicine, 2012, 53, 1253-1261.	2.8	120
9	Diagnostic Usefulness of Fluorineâ€“18-Î±â€“Methyltyrosine Positron Emission Tomography in Combination With 18 F-Fluorodeoxyglucose in Sarcoidosis Patients. Chest, 2007, 131, 1019-1027.	0.4	119
10	Pulmonary Pleomorphic Carcinoma: A Clinicopathological Study Including EGFR Mutation Analysis. Journal of Thoracic Oncology, 2010, 5, 460-465.	0.5	107
11	Fluorine-18-Î±-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study. Clinical Cancer Research, 2007, 13, 6369-6378.	3.2	99
12	Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer, 2014, 83, 197-204.	0.9	98
13	Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Research, 2010, 30, 4819-28.	0.5	95
14	Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer, 2013, 13, 482.	1.1	81
15	Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer, 2010, 67, 194-197.	0.9	79
16	2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. European Journal of Cancer, 2018, 101, 181-190.	1.3	77
17	Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer. Nature Communications, 2020, 11, 4607.	5.8	69
18	CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases. Annals of Surgical Oncology, 2009, 16, 3473-3481.	0.7	65

#	Article	IF	Citations
19	Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer, 2009, 66, 120-126.	0.9	65
20	Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer, 2010, 68, 99-104.	0.9	64
21	Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated nonâ€small cell lung cancer patients. Thoracic Cancer, 2019, 10, 775-781.	0.8	64
22	Expression of Lâ€type amino acid transporter 1 (<scp>LAT</scp>1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Science, 2014, 105, 1496-1502.	1.7	54
23	Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathology Research and Practice, 2008, 204, 553-561.	1.0	53
24	A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer, 2010, 69, 99-104.	0.9	53
25	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Research, 2015, 25, 399-405.	0.6	52
26	Expression of amino acid transporters (<scp>LAT1</scp>, <scp>ASCT2</scp> and <scp>xCT</scp>) as clinical significance in hepatocellular carcinoma. Hepatology Research, 2015, 45, 1014-1022.	1.8	51
27	LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. American Journal of Translational Research (discontinued), 2011, 3, 468-78.	0.0	51
28	Correlation of angiogenesis with ¹⁸Fâ€FMT and ¹⁸Fâ€FDG uptake in nonâ€small cell lung cancer. Cancer Science, 2009, 100, 753-758.	1.7	50
29	Lâ€type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I nonâ€small cell lung cancer. Histopathology, 2009, 54, 804-813.	1.6	49
30	¹⁸F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2009, 50, 1770-1776.	2.8	47
31	Correlation Between ¹⁸F-FDG Uptake on PET and Molecular Biology in Metastatic Pulmonary Tumors. Journal of Nuclear Medicine, 2011, 52, 705-711.	2.8	46
32	Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. European Journal of Cancer, 2012, 48, 1244-1254.	1.3	46
33	Clinical significance of postâ€progression survival in lung cancer. Thoracic Cancer, 2017, 8, 379-386.	0.8	46
34	High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. British Journal of Cancer, 2017, 116, 1177-1185.	2.9	46
35	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer, 2018, 119, 71-77.	0.9	46
36	Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 725.	1.0	46

#	Article	IF	Citations
37	Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 141-153.	1.1	45
38	Radiotherapy is an independent prognostic marker of favorable prognosis in nonâ€small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thoracic Cancer, 2019, 10, 992-1000.	0.8	44
39	Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer, 2010, 67, 120-123.	0.9	43
40	Prognostic significance of Lâ€type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Science, 2009, 100, 249-254.	1.7	42
41	Efficacy of system <scp>l</scp> amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Science, 2016, 107, 1499-1505.	1.7	40
42	<scp>L</scp>â€type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. Journal of Surgical Oncology, 2009, 99, 433-438.	0.8	39
43	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer, 2018, 126, 41-47.	0.9	39
44	Biologic correlates of 18F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Lung Cancer, 2011, 71, 144-150.	0.9	38
45	Diagnostic usefulness of 18F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1692-1700.	3.3	38
46	Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. Journal of Surgical Oncology, 2016, 113, 381-389.	0.8	38
47	Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma. British Journal of Cancer, 2020, 122, 1686-1694.	2.9	38
48	Clinicopathological significance of <scp>ASC</scp> amino acid transporterâ€2 expression in pancreatic ductal carcinoma. Histopathology, 2015, 66, 234-243.	1.6	37
49	Clinical and Pathological Significance of ER Stress Marker (BiP/GRP78 and PERK) Expression in Malignant Melanoma. Pathology and Oncology Research, 2017, 23, 111-116.	0.9	37
50	Chemoradiotherapy followed by durvalumab in patients with unresectable advanced nonâ€small cell lung cancer: Management of adverse events. Thoracic Cancer, 2020, 11, 1280-1287.	0.8	37
51	Evaluation of thoracic tumors with ¹⁸Fâ€FMT and ¹⁸Fâ€FDG PETâ€CT: A clinicopathological study. International Journal of Cancer, 2009, 124, 1152-1160.	2.3	36
52	Specific transport of 3â€fluoroâ€<scp>l</scp>â€Îąâ€methylâ€tyrosine by <scp>LAT</scp>1 explains its specificity to malignant tumors in imaging. Cancer Science, 2016, 107, 347-352.	1.7	35
53	High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors. Annals of Surgical Oncology, 2020, 27, 933-942.	0.7	35
54	Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma. Pathology and Oncology Research, 2015, 21, 1175-1181.	0.9	34

#	Article	IF	Citations
55	Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma. Journal of Global Oncology, 2017, 3, 360-369.	0.5	34
56	Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 873-880.	1.1	32
57	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 761-771.	1.1	32
58	Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer, 2015, 15, 989.	1.1	31
59	High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. Annals of Surgical Oncology, 2017, 24, 4017-4024.	0.7	31
60	Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1. Anticancer Research, 2019, 39, 1455-1461.	0.5	31
61	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (United States), 2020, 99, e19059.	0.4	30
62	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Annals of Thoracic Medicine, 2015, 10, 61-6.	0.7	30
63	L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Research, 2011, 31, 4075-82.	0.5	30
64	The role of Î²III-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. International Journal of Clinical Oncology, 2013, 18, 371-379.	1.0	27
65	Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma. Anticancer Research, 2019, 39, 3039-3046.	0.5	27
66	Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Experimental and Therapeutic Medicine, 2010, 1, 799-808.	0.8	26
67	18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Annals of Nuclear Medicine, 2011, 25, 247-253.	1.2	26
68	Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Medical Oncology, 2012, 29, 1663-1672.	1.2	26
69	Expression of amino acid transporter (LAT1 and 4F2hc) in pulmonary pleomorphic carcinoma. Human Pathology, 2019, 84, 142-149.	1.1	26
70	Biological correlation of Â¹â¸F-FDG uptake on PET in pulmonary neuroendocrine tumors. Anticancer Research, 2013, 33, 4219-28.	0.5	26
71	MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 615-620.	1.4	25
72	Depolarized MUC1 Expression Is Closely Associated With Hypoxic Markers and Poor Outcome in Resected Nonâ€“Small Cell Lung Cancer. International Journal of Surgical Pathology, 2012, 20, 223-232.	0.4	25

#	Article	IF	Citations
73	Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma. Acta Oto-Laryngologica, 2016, 136, 1-7.	0.3	25
74	Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer, 2019, 134, 180-186.	0.9	25
75	Different incidence of interstitial lung disease according to different kinds of EGFRâ€tyrosine kinase inhibitors administered immediately before and/or after antiâ€PDâ€1 antibodies in lung cancer. Thoracic Cancer, 2019, 10, 975-979.	0.8	25
76	FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Research and Treatment, 2020, 181, 331-338.	1.1	25
77	Value of FDG Positron Emission Tomography in Monitoring the Effects of Therapy in Progressive Pulmonary Sarcoidosis. Clinical Nuclear Medicine, 2007, 32, 114-116.	0.7	24
78	Barium sulphate aspiration. Lancet, The, 2004, 364, 2220.	6.3	23
79	Comparison of l-type amino acid transporter 1 expression and l-[3-18F]-Î±-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nuclear Medicine and Biology, 2010, 37, 911-916.	0.3	23
80	Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1Ââ‰¥Â50%. Scientific Reports, 2020, 10, 14990.	1.6	23
81	Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. American Journal of Translational Research (discontinued), 2015, 7, 1126-39.	0.0	23
82	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. American Journal of Translational Research (discontinued), 2015, 7, 1161-71.	0.0	23
83	CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma. Head and Neck, 2015, 37, 1569-1574.	0.9	22
84	Prognostic role of BiP/GRP78 expression as ER stress in patients with gastric adenocarcinoma. Cancer Biomarkers, 2017, 20, 273-281.	0.8	22
85	Î²2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment, 2019, 177, 603-610.	1.1	22
86	First-line gefitinib treatment in elderly patients (aged â‰¥75Âyears) with non-small cell lung cancer harboring EGFR mutations. Cancer Chemotherapy and Pharmacology, 2015, 76, 761-769.	1.1	21
87	Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. Anticancer Research, 2019, 39, 2535-2543.	0.5	21
88	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged â‰¥â€‰75Âyears) with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 457-466.	1.2	21
89	Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 23, 85-88.	0.9	21
90	Pretreatment Glasgow prognostic score predicts survival among patients with high PDâ€L1 expression administered firstâ€line pembrolizumab monotherapy for nonâ€small cell lung cancer. Cancer Medicine, 2021, 10, 6971-6984.	1.3	21

#	Article	IF	Citations
91	Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers. Cancer Imaging, 2021, 21, 11.	1.2	21
92	Management of Malignant Pericardial Effusion with Instillation of Mitomycin C in Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 57-60.	0.6	20
93	Fulminant hepatic failure resulting from small-cell lung cancer and dramatic response of chemotherapy. World Journal of Gastroenterology, 2006, 12, 2466.	1.4	20
94	Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer, 2011, 74, 419-425.	0.9	20
95	Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer, 2013, 82, 449-454.	0.9	20
96	Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene. Molecular and Clinical Oncology, 2014, 2, 731-736.	0.4	20
97	L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer. Anticancer Research, 2010, 30, 4223-7.	0.5	20
98	Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncology Reports, 2011, 26, 931-7.	1.2	19
99	18F-FAMT in patients with multiple myeloma: clinical utility compared to 18F-FDG. Annals of Nuclear Medicine, 2012, 26, 811-816.	1.2	19
100	The role of [Â¹â¸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging, 2011, 11, 195-201.	1.2	19
101	18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study. European Journal of Radiology, 2012, 81, 2423-2429.	1.2	18
102	Biological evaluation of 3-[18F]fluoro-Î±-methyl-d-tyrosine (d-[18F]FAMT) as a novel amino acid tracer for positron emission tomography. Annals of Nuclear Medicine, 2013, 27, 314-324.	1.2	18
103	Forearm Muscle Metastasis as an Initial Clinical Manifestation of Lung Cancer. Southern Medical Journal, 2009, 102, 79-81.	0.3	17
104	Highâ€grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. Journal of Surgical Oncology, 2010, 102, 11-17.	0.8	17
105	Decreased expression of class III Î²-tubulin is associated with unfavourable prognosis in patients with malignant melanoma. Melanoma Research, 2016, 26, 29-34.	0.6	17
106	Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients. Journal of Surgical Oncology, 2017, 116, 706-715.	0.8	17
107	Preâ€existing interstitial lung disease does not affect prognosis in nonâ€small cell lung cancer patients with <scp>PDâ€L1</scp> expression â‰¥50% on firstâ€line pembrolizumab. Thoracic Cancer, 2021, 12, 304-313.	0.8	17
108	A systemic review of PET and biology in lung cancer. American Journal of Translational Research (discontinued), 2011, 3, 383-91.	0.0	17

#	Article	IF	Citations
109	Assessment of Therapy Response in Lung Cancer With ¹⁸F-Î±-Methyl Tyrosine PET. American Journal of Roentgenology, 2010, 195, 1204-1211.	1.0	16
110	Clinicopathological Significance of L-type Amino Acid Transporter 1 (LAT1) Expression in Patients with Adenoid Cystic Carcinoma. Pathology and Oncology Research, 2013, 19, 649-656.	0.9	16
111	¹⁸F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma. Acta Oto-Laryngologica, 2015, 135, 494-499.	0.3	16
112	Clinical significance of Î²2-adrenergic receptor expression in patients with surgically resected gastric adenocarcinoma. Tumor Biology, 2016, 37, 13885-13892.	0.8	16
113	Prognostic significance of Î²2-adrenergic receptor expression in malignant melanoma. Tumor Biology, 2016, 37, 5971-5978.	0.8	16
114	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 497-505.	1.1	16
115	High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. Oncology Letters, 2018, 15, 3061-3067.	0.8	16
116	Fucosylated Î±1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. Scientific Reports, 2019, 9, 14503.	1.6	16
117	Prognostic Impact of Î²2 Adrenergic Receptor Expression in Surgically Resected Pulmonary Pleomorphic Carcinoma. Anticancer Research, 2019, 39, 395-403.	0.5	16
118	Prognostic significance of Î²2-adrenergic receptor expression in non-small cell lung cancer. American Journal of Translational Research (discontinued), 2016, 8, 5059-5070.	0.0	16
119	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung. American Journal of Translational Research (discontinued), 2018, 10, 3243-3253.	0.0	16
120	Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and Î² III-Tubulin in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2011, 6, 606-613.	0.5	15
121	MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer. Pathology and Oncology Research, 2012, 18, 439-447.	0.9	15
122	Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy. Medical Oncology, 2014, 31, 88.	1.2	15
123	Decreasing expression of glucoseâ€regulated protein GRP78/BiP as a significant prognostic predictor in patients with advanced laryngeal squamous cell carcinoma. Head and Neck, 2016, 38, 1539-1544.	0.9	15
124	Transport of 3-fluoro-l-Î±-methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [18F]FAMT positron emission tomography. Journal of Pharmacological Sciences, 2016, 130, 101-109.	1.1	15
125	STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma. Clinical Cancer Research, 2017, 23, 3442-3452.	3.2	15
126	Sodium Glucose Cotransporter 2 Inhibition Combined With Cetuximab Significantly Reduced Tumor Size and Carcinoembryonic Antigen Level in Colon Cancer Metastatic to Liver. Clinical Colorectal Cancer, 2018, 17, e45-e48.	1.0	15

#	Article	IF	Citations
127	Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. Oncologist, 2020, 25, e668-e674.	1.9	15
128	Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced nonâ€small cell lung cancer in comparison with chemoradiotherapy alone. Thoracic Cancer, 2021, 12, 245-250.	0.8	15
129	Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. American Journal of Translational Research (discontinued), 2015, 7, 356-63.	0.0	15
130	Relationship between LAT1 expression and response to platinum-based chemotherapy in non-small cell lung cancer patients with postoperative recurrence. Anticancer Research, 2011, 31, 3775-82.	0.5	15
131	Laryngeal Sarcoidosis Detected by FDG Positron Emission Tomography. Clinical Nuclear Medicine, 2008, 33, 878-879.	0.7	14
132	Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. Annals of Nuclear Medicine, 2010, 24, 697-705.	1.2	14
133	CD98 is a promising prognostic biomarker in biliary tract cancer. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 654-657.	0.6	14
134	High stathmin 1 expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. International Journal of Oncology, 2017, 50, 1184-1190.	1.4	14
135	Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with nonâ€small cell lung cancer harboring EGFR mutation. Thoracic Cancer, 2020, 11, 1045-1051.	0.8	14
136	CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. Oncology Reports, 2010, 24, 861-7.	1.2	14
137	Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 440-445.	1.1	13
138	Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis. Cancer Chemotherapy and Pharmacology, 2017, 79, 209-213.	1.1	13
139	A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 615-622.	1.1	13
140	Accumulation of periostin in acute exacerbation of familial idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2018, 10, E587-E591.	0.6	13
141	Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation. Cancer Chemotherapy and Pharmacology, 2019, 83, 817-825.	1.1	13
142	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. Cancer Science, 2020, 111, 1969-1978.	1.7	13
143	Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Scientific Reports, 2022, 12, 2742.	1.6	13
144	Realâ€world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensiveâ€disease smallâ€cell lung cancer. Cancer Medicine, 2023, 12, 73-83.	1.3	13

#	Article	IF	Citations
145	A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anti-Cancer Drugs, 2007, 18, 471-476.	0.7	12
146	Pulmonary traumatic pneumatocele and hematoma. Japanese Journal of Radiology, 2009, 27, 100-102.	1.0	12
147	Small-cell lung cancer with voltage-gated calcium channel antibody-positive paraneoplastic limbic encephalitis: a case report. Journal of Medical Case Reports, 2014, 8, 119.	0.4	12
148	Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide. Canadian Respiratory Journal, 2016, 2016, 1-8.	0.8	12
149	Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 165-171.	1.1	12
150	High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. International Journal of Clinical Oncology, 2017, 22, 872-879.	1.0	11
151	Osimertinib induced cardiomyopathy. Medicine (United States), 2020, 99, e22301.	0.4	11
152	Glasgow prognostic score predicts efficacy and prognosis in patients with advanced nonâ€small cell lung cancer receiving EGFRâ€TKI treatment. Thoracic Cancer, 2020, 11, 2188-2195.	0.8	11
153	Prognostic significance of Î²2-adrenergic receptor expression in patients with surgically resected colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1137-1144.	1.0	11
154	Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. Journal of Clinical Medicine, 2021, 10, 3744.	1.0	11
155	Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anti-Cancer Drugs, 2005, 16, 455-460.	0.7	10
156	Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 2010, 68, 253-257.	0.9	10
157	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. Chemotherapy, 2017, 62, 205-213.	0.8	10
158	A new enzyme immunoassay for the determination of highly sialylated and fucosylated human Î± 1 -acid glycoprotein as a biomarker of tumorigenesis. Clinica Chimica Acta, 2018, 478, 120-128.	0.5	10
159	Severe Thrombocytopenia Associated With Pembrolizumab in Patients With Non-small Cell Lung Cancer (NSCLC): A Case Report and Literature Review. In Vivo, 2020, 34, 877-880.	0.6	10
160	Effectiveness of EGFRâ€TKI rechallenge immediately after PD â€1 blockade failure. Thoracic Cancer, 2021, 12, 864-873.	0.8	10
161	Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Frontiers in Oncology, 2021, 11, 610952.	1.3	10
162	Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine. BMC Cancer, 2020, 20, 935.	1.1	10

#	Article	IF	Citations
163	Primary Mediastinal Synovial Sarcoma. Journal of Computer Assisted Tomography, 2008, 32, 238-241.	0.5	9
164	Phase I Study of Oral S-1 Plus Cisplatin With Concurrent Radiotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 109-114.	0.4	9
165	High expression of nucleobindin 2 is associated with poor prognosis in gastric cancer. Tumor Biology, 2017, 39, 101042831770381.	0.8	9
166	Clinical significance of primary prophylactic pegylatedâ€granulocyteâ€colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1005-1008.	0.8	9
167	Usefulness of 18F-Î±-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer. Anticancer Research, 2016, 36, 6481-6490.	0.5	9
168	Prognostic Significance of the Expression of CD98 (4F2hc) in Gastric Cancer. Anticancer Research, 2017, 37, 631-636.	0.5	9
169	Clinical Significance and Phenotype of MTA1 Expression in Esophageal Squamous Cell Carcinoma. Anticancer Research, 2017, 37, 4147-4155.	0.5	9
170	Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. Anticancer Research, 2011, 31, 2763-71.	0.5	9
171	Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer. Investigational New Drugs, 2022, 40, 1066-1079.	1.2	9
172	Prognostic and predictive factors in resected non-small-cell lung cancer. Expert Opinion on Medical Diagnostics, 2010, 4, 373-381.	1.6	8
173	The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients. Investigational New Drugs, 2015, 33, 755-760.	1.2	8
174	Prognostic value of metabolic tumor volume of pretreatment 18F-FAMT PET/CT in non-small cell lung Cancer. BMC Medical Imaging, 2018, 18, 46.	1.4	8
175	Stathmin-1 Is a Useful Diagnostic Marker for High-Grade Lung Neuroendocrine Tumors. Annals of Thoracic Surgery, 2019, 108, 235-243.	0.7	8
176	Postâ€progression survival is highly linked to overall survival in patients with nonâ€smallâ€cell lung cancer harboring sensitive EGFR mutations treated with firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitors. Thoracic Cancer, 2019, 10, 2200-2208.	0.8	8
177	Severe gastritis due to pembrolizumab treatment in a lung cancer patient. Respirology Case Reports, 2020, 8, e00636.	0.3	8
178	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. Supportive Care in Cancer, 2020, 28, 4825-4831.	1.0	8
179	Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation. Environmental Science and Technology Letters, 2021, 8, 903-910.	3.9	8
180	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status. Medicina (Lithuania), 2021, 57, 1273.	0.8	8

#	Article	IF	Citations
181	A Phase I Dose Escalation Study of Weekly Docetaxel and Carboplatin in Elderly Patients With Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 51-56.	0.6	7
182	Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. Anti-Cancer Drugs, 2008, 19, 289-294.	0.7	7
183	High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. Lung Cancer, 2018, 115, 42-48.	0.9	7
184	Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. Cancer Chemotherapy and Pharmacology, 2019, 84, 655-660.	1.1	7
185	Drastic Response of Re-challenge of EGFR-TKIs Immediately After Nivolumab Therapy in EGFR-TKIâ€"Resistant Patients. Journal of Thoracic Oncology, 2019, 14, e135-e136.	0.5	7
186	Relationship Between Tumor Immune Markers and Fluorine-18-Î±-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer. Molecular Imaging and Biology, 2020, 22, 1078-1086.	1.3	7
187	Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib. Journal of Thoracic Oncology, 2020, 15, e54-e55.	0.5	7
188	Course of postoperative relapse in nonâ€small cell lung cancer is strongly associated with postâ€progression survival. Thoracic Cancer, 2021, 12, 2740-2748.	0.8	7
189	B-Cell Non-Hodgkin Lymphoma Presenting As an Endobronchial Polypoid Mass. Journal of Thoracic Oncology, 2008, 3, 530-531.	0.5	6
190	Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. Lung Cancer, 2013, 82, 103-108.	0.9	6
191	Prognostic effect of class III Î²-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncology Letters, 2017, 14, 2369-2378.	0.8	6
192	Dual inhibition of MEK and p38 impairs tumor growth in KRASâ€'mutated nonâ€'small cell lung cancer. Oncology Letters, 2019, 17, 3569-3575.	0.8	6
193	Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy. Anticancer Research, 2020, 40, 3513-3517.	0.5	6
194	Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms. In Vivo, 2021, 35, 2425-2432.	0.6	6
195	Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy. Journal of Radiation Research, 2021, 62, 669-675.	0.8	6
196	Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer. Journal of Radiation Research, 2021, 62, 894-900.	0.8	6
197	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 1479-1489.	0.8	6
198	Coinfection of invasive pulmonary aspergillosis and pneumocystis jiroveci pneumonia in a non-HIV patient. Acta Medica Okayama, 2007, 61, 235-8.	0.1	6

#	Article	IF	Citations
199	Rapid Growth of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2007, 2, 966-967.	0.5	5
200	Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6. International Journal of Clinical Oncology, 2009, 14, 534-536.	1.0	5
201	Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients withpostoperative recurrence following platinum-based chemotherapy. Respiratory Investigation, 2014, 52, 121-128.	0.9	5
202	18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms. Oncology Reports, 2014, 31, 209-215.	1.2	5
203	Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFRâ€"TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations. Cancer Chemotherapy and Pharmacology, 2018, 82, 119-127.	1.1	5
204	Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels. Medicina (Lithuania), 2019, 55, 161.	0.8	5
205	Treatment with Tumor Necrosis Factor-Î± Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients. Journal of Clinical Medicine, 2020, 9, 96.	1.0	5
206	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. Cancers, 2021, 13, 1065.	1.7	5
207	Comprehensive expressional analysis of chemosensitivityâ€related markers in large cell neuroendocrine carcinoma of the lung. Thoracic Cancer, 2021, 12, 2666-2679.	0.8	5
208	Tumor immunity is related to ¹⁸Fâ€FDG uptake in thymic epithelial tumor. Cancer Medicine, 2021, 10, 6317-6326.	1.3	5
209	Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib. Journal of Cancer Research and Therapeutics, 2020, 16, 919.	0.3	5
210	Phase I Study of Biweekly Paclitaxel and Carboplatin for Frail Patients With Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 487-491.	0.6	4
211	18F-FDG uptake on PET could be aâ€predictive marker of Excision Repair Cross-Complementation Group 1 (ERCC1) expression in patients with thoracic neoplasms?. Neoplasma, 2012, 59, 257-263.	0.7	4
212	Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma. Cancers, 2019, 11, 1636.	1.7	4
213	Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma. Anticancer Research, 2020, 40, 261-269.	0.5	4
214	Clinical significance of topoisomeraseâ€II expression in patients with advanced nonâ€small cell lung cancer treated with amrubicin. Thoracic Cancer, 2020, 11, 426-435.	0.8	4
215	Primary thymic adenocarcinoma with an aggressive clinical course: An autopsy case showing signet ring cellâ€like features. Thoracic Cancer, 2020, 11, 3609-3613.	0.8	4
216	Efficacy and safety of S â€1 monotherapy in previously treated elderly patients (aged â‰¥75â€‰years) with nonâ€small cell lung cancer: A retrospective analysis. Thoracic Cancer, 2020, 11, 2867-2876.	0.8	4

#	Article	IF	Citations
217	Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma. Journal of Clinical Medicine, 2020, 9, 413.	1.0	4
218	Efficacy and Safety of Anti-Programed Death-1 Blockade in Previously Treated Large-Cell Neuroendocrine Carcinoma. Chemotherapy, 2021, 66, 65-71.	0.8	4
219	Plasma plastinâ€'3: A tumor marker in patients with nonâ€'smallâ€'cell lung cancer treated with nivolumab. Oncology Letters, 2020, 21, 1-1.	0.8	4
220	Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma. Cancers, 2021, 13, 5441.	1.7	4
221	Visual Assessment of 18F-FDG Uptake on PET to Predict Survival Benefit to PD-1 Blockade in Nonâ€"Small Cell Lung Cancer. Clinical Nuclear Medicine, 2022, 47, 108-116.	0.7	4
222	A retrospective study of the efficacy and safety of naldemedine for opioidâ€induced constipation in thoracic cancer patients. Thoracic Cancer, 2022, 13, 2301-2308.	0.8	4
223	Small cell carcinoma of the parotid gland. Otolaryngology - Head and Neck Surgery, 2007, 136, 330-331.	1.1	3
224	Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2016, 21, 240-247.	1.0	3
225	Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. Oncology Letters, 2017, 14, 1123-1128.	0.8	3
226	The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. Medical Oncology, 2018, 35, 45.	1.2	3
227	Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Thoracic Cancer, 2018, 9, 1699-1706.	0.8	3
228	An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 2483-2491.	0.5	3
229	Efficacy of PD-1 blockade therapy and T cell immunity in lung cancer patients. Immunological Medicine, 2020, 43, 10-15.	1.4	3
230	Stereotactic body radiation therapy using CyberKnife for T1N0M0 lung cancer patients with severe pulmonary dysfunction. Journal of Radiation Research, 2020, 61, 903-907.	0.8	3
231	A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74â€‰years old and patients with PS 0 or 1 from 75â€‰years: NEJ039A (trial in progress). BMC Cancer, 2020, 20, 961.	1.1	3
232	Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. Chemotherapy, 2020, 65, 21-28.	0.8	3
233	Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer. Anticancer Research, 2020, 40, 5309-5311.	0.5	3
234	Post-Progression Survival Influences Overall Survival among Patients with Advanced Non-Small Cell Lung Cancer Undergoing First-Line Pembrolizumab Monotherapy. Oncology, 2021, 99, 562-570.	0.9	3

#	Article	IF	Citations
235	Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from MycobacteriumÂtuberculosis: A case report. Molecular and Clinical Oncology, 2021, 15, 227.	0.4	3
236	Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations. Medicina (Lithuania), 2021, 57, 929.	0.8	3
237	Carbonic anhydrase 9 expression is associated with poor prognosis, tumor proliferation, and radiosensitivity of thymic carcinomas. Oncotarget, 2019, 10, 1306-1319.	0.8	3
238	Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study. Current Oncology, 2022, 29, 163-172.	0.9	3
239	Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer. Scientific Reports, 2022, 12, .	1.6	3
240	Dramatic Response of S-1 Administration to Chemorefractory Advanced Thymic Cancer. Chemotherapy, 2014, 60, 356-359.	0.8	2
241	Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer. Lung Cancer, 2020, 139, 221-223.	0.9	2
242	Occurrence of Hematological Malignancy in Long-term Survivors With Advanced Thymic Cancer. In Vivo, 2020, 34, 1511-1513.	0.6	2
243	A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199858.	1.4	2
244	Synchronous dilemma of sarcoid-like reaction and drastic response after PD-1 blockade administration in lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1179-1180.	0.6	2
245	Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations. Medicina (Lithuania), 2021, 57, 508.	0.8	2
246	Recurrent intimal sarcoma mimicking pulmonary embolism. Japanese Journal of Clinical Oncology, 2015, 45, 695-696.	0.6	1
247	Prognostic value of morphological characteristics assessed by CT scan in patients with nonâ€small cell lung cancer treated with nivolumab. Thoracic Cancer, 2020, 11, 3521-3527.	0.8	1
248	Detection of pseudoprogression with [18F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1268-1270.	3.3	1
249	Clinical impact of postâ€progression survival on overall survival in patients receiving nivolumab monotherapy as a secondâ€line treatment for advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1171-1179.	0.8	1
250	Post-Progression Survival Highly Influences Overall Survival in Driver Gene Mutation/Translocation Negative or Unknown Type of Non-Small Cell Lung Cancer. Oncology, 2022, 100, 89-100.	0.9	1
251	The Relationship between Tumor Development and Sarcoidosis in Aspects of Carcinogenesis before and after the Onset of Sarcoidosis. Medicina (Lithuania), 2022, 58, 768.	0.8	1
252	Pulmonary Pleomorphic Carcinoma: Diagnosis Using Small Biopsy Specimens. Journal of Thoracic Oncology, 2010, 5, 1492-1493.	0.5	0

#	Article	IF	Citations
253	Reply to: Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2018, 82, 369-369.	1.1	0
254	Spontaneous aspiration of a long tree twig as foreign body. Respirology Case Reports, 2019, 7, e00401.	0.3	0
255	Verrucous skin lesion caused by neuropathy misdiagnosed as squamous cell carcinoma and treated with amputation surgery. Journal of Dermatology, 2020, 47, e188-e190.	0.6	0
256	Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. Anticancer Research, 2020, 40, 1571-1578.	0.5	0
257	A 54ÂGy in three fractions of stereotactic body radiotherapy using CyberKnife for T1b-2aN0M0 pathologically confirmed non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1723-1728.	0.6	0
258	PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer. , 2017, , 45-61.		0
259	The Role of 18F-FDG-PET as Therapeutic Monitoring in Patients with Lung Cancer. , 2021, , 23-33.		0
260	Clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy. Radiology and Oncology, 2022, 56, 228-237.	0.6	0